Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
How does leptin restore euglycemia in insulin-deficient diabetes?
Douglas Oberlin, Christoph Buettner
Douglas Oberlin, Christoph Buettner
Published January 23, 2017
Citation Information: J Clin Invest. 2017;127(2):450-453. https://doi.org/10.1172/JCI91880.
View: Text | PDF
Commentary

How does leptin restore euglycemia in insulin-deficient diabetes?

  • Text
  • PDF
Abstract

Insulin replacement is the cornerstone of type 1 diabetes (T1D) treatment; however, glycemic control remains a challenge. Leptin has been shown to effectively restore euglycemia in rodent models of T1D; however, the mechanism or mechanisms by which leptin exerts glycemic control are unclear. In this issue of the JCI, Perry and colleagues provide evidence that suppression of lipolysis is a key facet of leptin-mediated restoration of euglycemia. However, more work remains to be done to fully understand the antidiabetic mechanisms of leptin.

Authors

Douglas Oberlin, Christoph Buettner

×

Figure 1

Model proposed by Perry et al. in this issue to explain the antidiabetic effects of leptin.

Options: View larger image (or click on image) Download as PowerPoint
Model proposed by Perry et al. in this issue to explain the antidiabetic...
Leptin restrains the activity of the HPA axis in T1D, reducing circulating corticosterone, which lowers lipolysis in adipose tissue. As of yet it remains unclear in what tissue and cell type GCs exert these lipolytic effects. Restrained lipolysis results in lower NEFAs and glycerol delivery to the liver, reducing gluconeogenesis and ketogenesis and thereby reversing hyperglycemia and DKA. PEPCK, phosphoenolpyruvate carboxykinase; G3P, glyceraldehyde 3-phosphate; HSL, hormone-sensitive lipase; PC, pyruvate carboxylase; βox, β oxidation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts